Skip to Main Content

Paper Details

Targeted gene panels identify a high frequency of pathogenic germline variants in patients diagnosed with a hematological malignancy and at least one other independent cancer.
Leukemia
34
2021
BRCA1, BRCA2, CHEK2, CPGs, DDX41, HM, HMs, MC, MC-HM, MN, PGVs, TP53, cancer, cancer predisposition genes, cancers, germline samples, germline variants, hematological malignancies, hematological malignancy, lymphoid, lymphoid and myeloid, malignancy, multiple cancers, pathogenic germline variants, patients, single cancers, t-MN, t-MNs, therapy-related myeloid neoplasms
Author NameAffiliation
Simone FeursteinThe University of Chicago
David M ThomasThe Kinghorn Cancer Centre, Garvan Institute of Medical Research
David M ThomasSt Vincent's Clinical School, University of New South Wales
David M Thomas
David M ThomasThe Kinghorn Cancer Centre, Garvan Institute of Medical Research
David M Thomas
David M ThomasSt Vincent's Clinical School, University of New South Wales
Anna L BrownAdelaide Medical School, University of Adelaide
Anna L Brown
Anna L BrownClinical and Health Sciences, University of South Australia
Nicola K PoplawskiAdelaide Medical School, University of Adelaide
Nicola K PoplawskiRoyal Adelaide Hospital
Nicola K PoplawskiAdelaide Medical School, University of Adelaide
Nicola K PoplawskiRoyal Adelaide Hospital
Lucy A GodleyThe University of Chicago
Lucy A GodleyThe University of Chicago
  • 1 - 16

Datasets

Release 1.2